Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
Rhea-AI Summary
Larimar Therapeutics (Nasdaq: LRMR) priced an upsized underwritten public offering of 20,000,000 common shares at $5.00 per share, yielding expected gross proceeds of $100 million before expenses. The underwriters have a 30‑day option for an additional 3,000,000 shares.
The offering is expected to close on or about February 27, 2026. Larimar said net proceeds will support development of nomlabofusp and fund working capital, R&D and commercialization expenses. The offering uses an effective Form S-3 shelf registration (effective May 24, 2024).
Positive
- Raised expected gross proceeds of $100 million
- Proceeds allocated to nomlabofusp development and R&D
Negative
- Issuance of 20,000,000 shares may cause shareholder dilution
- Underwriters hold a 30‑day option for 3,000,000 additional shares
News Market Reaction – LRMR
In the Feb 26 session, LRMR declined 7.23%, reflecting a notable negative market reaction. Argus tracked a peak move of +81.1% during that session. Our momentum scanner triggered 131 alerts that day, indicating very high trading interest and price volatility. Trading volume was exceptionally heavy at 14.4x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized underwritten public offering of 20,000,000 shares of its common stock at a price to the public of
J.P. Morgan and Guggenheim Securities are acting as joint bookrunning managers for the offering. LifeSci Capital and William Blair are acting as bookrunners for the offering. Citizens Capital Markets is acting as lead manager for the offering, and Jones is acting as co-manager for the offering.
Larimar intends to use the net proceeds from the offering to support the development of nomlabofusp and for working capital and general corporate purposes, including research and development expenses and commercialization expenses.
The offering is being made pursuant to a shelf registration statement on Form S-3 (File No. 333-279275) that was declared effective by the Securities and Exchange Commission (“SEC”) on May 24, 2024. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC on February 25, 2026 and is available for free on the SEC’s website at www.sec.gov. A final prospectus supplement with the final terms of the offering and accompanying prospectus will be filed with the SEC and will be available for free on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from J.P. Morgan Securities LLC, Attention: c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544 or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that state or jurisdiction.
About Larimar Therapeutics, Inc.
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, nomlabofusp, is being developed as a potential treatment for Friedreich’s ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions, or statements regarding intent, belief, or current expectations are forward-looking statements and reflect the current beliefs of Larimar’s management. Such forward-looking statements include, without limitation, statements relating to the timing for completion of the public offering, and the use of proceeds and anticipated total gross proceeds from the public offering of common stock. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and other factors that could cause actual results and events to differ materially and adversely from those indicated by such forward-looking statements including, among others: risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the public offering, completion of the public offering, and other risks and uncertainties related to the public offering, as well as the risks and uncertainties set forth in the “Risk Factors” section and elsewhere in the prospectus supplement related to the public offering filed with the Securities and Exchange Commission and in our other filings with the Securities and Exchange Commission and available at www.sec.gov, including but not limited to Larimar’s periodic reports, including Larimar’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements that we make in this announcement speak only as of the date of this press release, and Larimar assumes no obligation to update forward-looking statements whether as a result of new information, future events or otherwise after the date of this press release, except as required under applicable law.
Investor Contact:
Joyce Allaire
LifeSci Advisors jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
